Saturday, July 11, 2026

Drug profile · INN

trimethoprim hydrochloride

trimethoprim hydrochloride (PRIMSOL) is a bacterial dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — trimethoprim hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

trimethoprim hydrochloride (PRIMSOL) is a bacterial dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN trimethoprim hydrochloride
Brand PRIMSOL
Mechanism Bacterial dihydrofolate reductase inhibitor
Target Dihydrofolate reductase
Route ORAL
Formulation SOLUTION

Mechanism of action

Bacterial dihydrofolate reductase inhibitor

Primary target: Dihydrofolate reductase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aminosalicylate sodium Dihydrofolate reductase inhibitor
  2. methotrexate sodium Dihydrofolate reductase inhibitor
  3. pemetrexed disodium Thymidylate synthase inhibitor
  4. pemetrexed sodium Thymidylate synthase inhibitor
  5. pralatrexate Antineoplastic and immunomodulating agents (L01)
  6. pyrimethamine Dihydrofolate reductase inhibitor

Frequently asked questions

What is trimethoprim hydrochloride?

trimethoprim hydrochloride (PRIMSOL) is a bacterial dihydrofolate reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for trimethoprim hydrochloride?

PRIMSOL is a marketed brand name for trimethoprim hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of trimethoprim hydrochloride?

trimethoprim hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.